Exobiosphere has secured €2 million in seed funding to enhance its microgravity drug discovery platform, positioning itself at the forefront of innovative pharmaceutical research.

Target Information

Exobiosphere, a pioneering contract research organization focused on drug discovery in space, has successfully secured over €2 million in a seed funding round aimed at scaling its innovative orbital high-throughput screening platform. The company stands out as the first of its kind, dedicated specifically to pharmaceutical research under microgravity conditions, which presents unique opportunities for enhancing drug development processes.

The funding will primarily be used to advance the development of Exobiosphere's Orbital High-Throughput Screeneer (OHTS), a state-of-the-art platform engineered for conducting drug tests in space. This initiative seeks to address significant inefficiencies in pharmaceutical research and development, where drug failure rates can exceed 90% and costs can reach billions over extensive timelines.

Industry Overview

In recent years, the pharmaceutical industry has faced mounting challenges due to high failure rates of drug candidates and elongated development cycles. With the advent of new technologies and methodologies, there is a growing push for